NITI Aayog, the leading think tank of the Indian government, has set up a committee aimed at creating a roadmap to elevate AIIMS, New Delhi, into a top-tier institution for medical research and healthcare excellence. The committee, led by NITI Aayog member VK Paul, will review existing systems and suggest reforms along with specific timelines for their execution. This initiative is part of a larger strategy to improve healthcare infrastructure, governance, and self-reliance at AIIMS.
Furthermore, NITI Aayog has been focusing on Universal Health Coverage (UHC) and making treatments for rare diseases more affordable, collaborating with the CSEP Research Foundation to study global UHC models. It has also promoted the local production of cost-effective drugs for rare diseases, leading to a significant decrease in treatment expenses.
Key Highlights of AIIMS Transformation Panel
Committee Formation
- Led by VK Paul, focusing on AIIMS New Delhi’s transformation.
Objectives
• Evaluate existing systems and suggest reforms with specific timelines.
• Optimize patient flow management and strengthen hospital governance.
• Establish Key Performance Indicators (KPIs) for excellence in clinical, academic, and research areas.
• Promote financial responsibility and sustainability in AIIMS operations.
Focus Areas
- Governance & transparency.
- Research excellence.
- Clinical & academic improvements.
- Self-sufficiency & financial sustainability.
NITI Aayog’s Efforts on Universal Health Coverage (UHC)
- Partnership with CSEP Research Foundation to study global UHC models.
Draft paper on healthcare financing strategies,
- Addresses supply-side & demand-side financing.
- Aims to improve healthcare accessibility, quality, and affordability.
- Extensive government & stakeholder consultations planned to shape policies.
Rare Disease Drug Accessibility Initiative
- Effort to provide affordable indigenous treatments for rare diseases.
- 4 affordable drugs introduced, priced at 1/60th to 1/100th of imported versions.
- 4 more drugs undergoing regulatory approval, expected to launch by year-end.
